Invitation

(Non-Transferable)

Drs. Anna D. Barker and Laura Esserman
On behalf of the
Quantum Leap Healthcare Collaborative™ (QLHC) Board of Directors
Invite you to join us to learn about
The Impact of the Innovative I-SPY 2 Trial on the Treatment of High Risk Breast Cancer

The core of the I-SPY 2 platform trial for high-risk breast cancer is a Bayesian statistics-driven adaptive design that evaluates single investigational drugs and biologics versus standard of care in the neo-adjuvant setting. I-SPY-2 has shown that treatments that eliminate tumor prior to surgery dramatically improves survival in high-risk early stage breast cancer patients. The I-SPY 2 program is now continuing to innovate and push trial design continuous learning through individual optimization. Over the next five years, our goal is to get 90% of patients cured, with less toxic therapies. By rapidly and efficiently testing new drugs and combinations, we will ensure that each patient receives the most appropriate therapy for their disease - and in doing so, also reduces the time and cost of drug/biologics development. New findings from I-SPY 2, along with the next stage of this patient-focused, transformative trial will be presented.

Join our distinguished panel of experts including senior leadership from the FDA, the I-SPY 2 team, and breast cancer survivors as we announce major advances from the trial to date and look to the future of innovation in these patient-centered clinical trials.
September 13, 2018
12:30 p.m. – 2:00 p.m.
(Light Lunch at 12:00 p.m.)

Immediately following this event, you are invited to attend the I-SPY 2 Science Writer’s Seminar where the I-SPY 2 team will present the adaptive trial model in detail and describe the many innovative features of this new generation of trials. The seminar will run from 2:15 p.m. – 4:00 p.m.

Kindly RSVP by September 1, 2018

By using the form below or contacting Kristen Zeitzer, Director of Marketing and Communications, directly:
Email: k.zeitzer@quantumleaphealth.org
Phone: 415-215-6893

Thank you! Your submission has been received.
Oops! Something went wrong while submitting the form.